Full Year Guidance
Organon does not provide GAAP financial measures on a forward-looking basis because the company cannot predict with reasonable certainty and without unreasonable effort, the ultimate outcome of legal proceedings, unusual gains and losses, the occurrence of matters creating GAAP tax impacts, and acquisition-related expenses. These items are uncertain, depend on various factors, and could be material to Organon's results computed in accordance with GAAP.
Full year 2024 actual results and 2025 financial guidance are presented below on a non-GAAP basis, except revenue.
| Full Year 2024 Actuals | Full Year 2025 Guidance | |
| Revenue | $6.403B | $6.125B-$6.325B |
| FX translation headwind | ~$80M | ~$200M |
| Adjusted gross margin | 61.6% | 60.0%-61.0% |
| SG&A | $1.57B/25% | Mid-20% range |
| R&D | $440M/6.9% | Upper single-digit |
| IPR&D* | $81M | - |
| Adjusted EBITDA margin (Non-GAAP) | 30.6% | 31.0%-32.0% |
| Interest | $520M | ~$510M |
| Depreciation | $126M | ~$135M |
| Effective non-GAAP tax rate | 18.8% | 22.5%-24.5% |
| Fully diluted weighted average shares outstanding | 259M | ~263M |
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.